Stockreport
Exploring Growth Trends in the Chemotherapy Induced Anemia Market: A Surge to USD 4.84 Billion by 2032 [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
There's potential in personalized medicine, optimized supply chains, and region-specific strategies to navigate complex global dynamics and enhance patient care delivery. Chemotherapy Induced Anemia Market Dublin, Dec. 16, 2025 (GLOBE NEWSWIRE) -- The "Chemotherapy Induced Anemia Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering. The chemotherapy induced anemia market grew from USD 2.70 billion in 2024 to USD 2.90 billion in 2025 and is set to reach USD 4.84 billion by 2032, registering a CAGR of 7.57% over the forecast period. Market expansion is fueled by rising cancer incidence, greater adoption of erythropoiesis stimulating agents, growth in biosimilar penetration, and advancements in supportive technologies. The sector is responding to both clinical complexities and increasing patient expectations, driving innovation in therapies and care delivery models worldwide. Scope & Segmentation This comprehensive analysis offers actionable i
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- Amgen (NASDAQ:AMGN) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=AMGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from[MarketBeat]
- FDA Approves Amgen's UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease [Yahoo! Finance][Yahoo! Finance]
- Amgen (NASDAQ:AMGN) was given a new $304.00 price target on by analysts at Morgan Stanley.[MarketBeat]
- FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS [Yahoo! Finance][Yahoo! Finance]
- FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS[PR Newswire]
- More
AMGN
SEC Filings
SEC Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/13/25 - Form 4
- AMGN's page on the SEC website
- More